Lindus Health raises $55 million in Series B funding to scale up its eClinical platform

Lindus Health, a provider of end-to-end AI-powered clinical trials for life sciences companies, raised $55 million in Series B funding.

Balderton Capital led the investment round with participation from Visionaries Club, Creandum, Firstminute, and Seedcamp. 

This Series B funding is intended to further the Lindus Health mission of transforming the clinical trial landscape by leveraging artificial intelligence.

Lindus Health is a clinical research organization (CRO) that aims to revolutionize the traditional clinical trial process. Launched in 2021, with $5 million seed funding, the company has been conducting clinical trials across Europe and the U.S., focusing on conditions such as asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome, and insomnia.

Lindus Health offers an all-in-one CRO solution that encompasses study management, site operations, and technology necessary to operate a study, from building the protocol through to delivering data. Their in-house Citrus™ eClinical platform includes electronic data capture (EDC), clinical trial management system (CTMS), and more, aiming to deliver faster study startups and recruitment timelines.

Lindus Health said it will use the fresh funds to develop its AI technology and eClinical platform, Citrus, to optimize study design, automate central monitoring of study data and enable instant biostatistics.

Including the latest funding round, Lindus Health has raised over $80 million in funding to date, from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp.

“The last 20 years have seen huge breakthroughs in fundamental scientific research, but this isn’t impacting the general population because of the artificial bottleneck that clinical trials create,” said Michael Young, co-founder of Lindus Health. “We’re fixing that with a new paradigm for running trials underpinned by technology. That doesn’t just lead to faster trials, it changes the way companies can think about drug development going from waterfall big bets to agile research.”